Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(10 years ago) | |
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(10 years ago) | |
US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(9 years ago) | |
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(9 years ago) | |
US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(4 years ago) | |
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(4 years ago) |
Cymbalta is owned by Lilly.
Cymbalta contains Duloxetine Hydrochloride.
Cymbalta has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Cymbalta are:
Cymbalta was authorised for market use on 03 August, 2004.
Cymbalta is available in capsule, delayed rel pellets;oral dosage forms.
Cymbalta can be used as management of fibromyalgia (fm), method of treating anxiety.
The generics of Cymbalta are possible to be released after 20 April, 2023.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Apr 20, 2023 |
M(M-61) | Oct 18, 2015 |
New Indication(I-632) | Nov 04, 2013 |
Pediatric Exclusivity(PED) | May 04, 2014 |
New Indication(I-617) | Nov 19, 2012 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Treatment: Method of treating anxiety; Management of fibromyalgia (fm)
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL